Abstract
This malignancy has fascinated physicians for more than 100 years because it produces easily identified tumor markers, the M protein and the Bence Jones protein. The plasma cell normally resides in the bone marrow. When it becomes malignant it spreads through the red marrow of bones in a manner similar to the leukemias, crowding out normal marrow elements. Unchecked, this leads to anemia, bleeding, and infection. Death occurs from one or more of these problems. The course of illness in plasma cell myeloma is considerably more complicated than in the leukemias because humoral immunity is compromised by insufficient antibody production by normal plasma cells as the number of these cells decreases. The M protein and the Bence Jones protein damage kidney function. However, the hallmark of the disease is bone destruction, either by the malignant cells or mediated through osteoclasts as shown by Mundy et al. (1974). Finally, hypercalcemia and excess urates may cause further problems in this unusual disease. Very little is known of the factor or factors which may incite myeloma, but radiation and excessive stimulation of immunity seem to be possibilities (Matanoski et al. 1975; Isobe and Osserman 1971). Myeloma is slightly more common in men than in women and is very rare before age 50. Incidence climbs steadily from 4.8 per 100,000 per year at ages 50–54 to 30.8 per 100,000 per year at ages 75–79, declining slightly after that as shown in Fig. 14.1. This is, indeed, a disease of the elderly. Diagnosis is often delayed because bone pain in the elderly suggests osteoporosis or metastatic carcinoma to many physicians before it suggests multiple myeloma.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Brook J, Bateman JR, Gocka EF, Nakamura E, Steinfeld JL (1973) Longterm low dose melphalan treatment of multiple myeloma. Arch Intern Med 131:545–548
Conklin R, Alexanian R (1975) Clinical classification of plasma cell myeloma. Arch Intern Med 135:139–143
Hoogstraten B (1981) Mollites et fragilitas ossium. J Kans Med Soc 82:463–465
Isobe T, Osserman EF (1971) Pathologic conditions associated with plasma cell dyscrasias, a study of 806 cases. Ann NY Acad Sci 190:507–518
Kyle RA, Greipp PR (1980) Smouldering multiple myeloma. N Engl J Med 302:1347–1349
Matanoski GM, Seltser R, Sartwell PE, Diamond EL, Elliott EA (1975) Current mortality rates of radiologists and other physician specialists, specific causes of death. Am J Epidemiol 101:199–210
Midwest Cooperative, Chemotherapy Group (1964) Multiple myeloma, general aspects of diagnosis, course and survival. JAMA 188:741–745
Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE (1974) Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 291:1041–1046
Southeastern Cancer Study Group (1975) Treatment of myeloma, comparison of melphalan, chlorambucil, and azathioprine. Arch Intern Med 135:157–162
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Holmes, F.F. (1983). Multiple Myeloma. In: Aging and Cancer. Recent Results in Cancer Research, vol 87. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82101-1_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-82101-1_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-82103-5
Online ISBN: 978-3-642-82101-1
eBook Packages: Springer Book Archive